Lung cancer organoids, a promising model still with long way to go

Ma, Heng-Hao; Zhu, Yuandong; Yu, Yaya; Xiao, Zhen-Zhen; Zhang, Haibo

doi:10.1016/j.critrevonc.2022.103610

Cited by 22 publications

(19 citation statements)

References 130 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…B27 supplements, N-acetylcysteine, nicotinamide, SB202190, FGF, and other supplements provide the necessary survival protection signals for cell growth and contribute to organoid formation, but the specific concentrations still need to be adjusted in experiment [70]. Y-27,632, WNT/R-spondin, and EGF may be detrimental to the growth of LUAD PDO [36,70]. Nutlin-3a and Palbociclib can be used to screen lung cancer cells with TP53 or RB1 mutations from normal organoids [13,36,70].…”

Section: Challenges and Limitations Of Lung Cancer Pdomentioning

confidence: 99%

“…Y-27,632, WNT/R-spondin, and EGF may be detrimental to the growth of LUAD PDO [36,70]. Nutlin-3a and Palbociclib can be used to screen lung cancer cells with TP53 or RB1 mutations from normal organoids [13,36,70]. This may contribute to the separation of tumor organoids harbored specific mutation but is not suitable for all samples in PDO purification because lung cancer driver mutations are diverse, and wild-type mutations in normal lung cells [71].…”

Section: Challenges and Limitations Of Lung Cancer Pdomentioning

confidence: 99%

“…Due to different success rates and low repeatability in different research groups [4,5,9,36,57], we need a standardized methodology. And it would be beneficial to create a database containing the PDO/AO culture system data and histological genetic information [4,70].…”

Section: Conclusion and Perspectivementioning

confidence: 99%

See 2 more Smart Citations

The application of patient-derived organoid in the research of lung cancer

et al. 2023

View full text Add to dashboard Cite

Lung cancer is the most common cancer and the leading cause of cancer-related death worldwide. However, mechanisms of its progression remained unclear and new treatments against this disease are rapidly emerging. As a novel preclinical model, patient-derived organoid (PDO) can also be established from the patient’s tumor tissue and cultured in the laboratory, which preserves the key biological characteristics of the original tumor. Compared to the patient-derived xenograft (PDX) model of lung cancer, the culture success rate is improved, and the time and cost of model establishment are largely reduced. PDO is also expected to provide a more individual model to predict the efficacy of anti-cancer treatment in vitro. This paper summarizes the current application of PDO in the translational research of lung cancer.

show abstract

Section: Challenges and Limitations Of Lung Cancer Pdomentioning

confidence: 99%

Section: Challenges and Limitations Of Lung Cancer Pdomentioning

confidence: 99%

See 1 more Smart Citation

The application of patient-derived organoid in the research of lung cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Generally, there was no big difference in these supplements in 3D culture medium since they provided the requisite conditions. For example, Human FGF7, FGF10, Noggin and R-spondin1 were important for the maintenance of stemness, B27 and Y-27632 could increase cell survival rate [33] . A83-01, a TGF-β/ALK5 inhibitor, was mainly used in organoids to prevent TGF-β induced growth inhibition [33] .…”

Section: Lung Adenocarcinoma Organoidsmentioning

confidence: 99%

“…For example, Human FGF7, FGF10, Noggin and R-spondin1 were important for the maintenance of stemness, B27 and Y-27632 could increase cell survival rate [33] . A83-01, a TGF-β/ALK5 inhibitor, was mainly used in organoids to prevent TGF-β induced growth inhibition [33] . Li et al also demonstrated that using a mechanical dissociation method in which organoids are smashed into small fragments using 10-mL Stripette Serological Pipets is a better option for the passages of organoids, with a success rate of 80% [32] .…”

Section: Lung Adenocarcinoma Organoidsmentioning

confidence: 99%

Organoids in lung cancer: A teenager with infinite growth potential

Xin

Yan

et al. 2022

Lung Cancer

View full text Add to dashboard Cite

Efficacy Evaluation of Adjuvant Therapeutic Drugs Against Early and Middle Stage Non‐Small Cell Lung Cancer Organoids

Liu,

Li,

Chen

et al. 2024

Advanced Therapeutics

View full text Add to dashboard Cite

Abstract30–55% post‐surgical recurrent rate of early and middle stage non‐small cell lung cancer (e/mNSCLC) suggests the need of adjuvant therapy. The e/mNSCLC derived organoids (e/mNSCLCOs)‐based efficacy evaluation of the proposed regimens may improve clinical benefits for e/mNSCLC patients. The e/mNSCLCOs are established from 33 IA‐IIIB resectable non‐small cell lung cancer (NSCLC) patients without systemic antitumor therapy via optimized 3D culture, of which six with epidermal growth factor receptor (EGFR) mutation. Immunohistochemical staining is employed to ascertain the maintenance of biomarker expression patterns of e/mNSCLCOs with that of their parental tumors. The e/mNSCLCOs are treated with six conventional anti‐NSCLC chemotherapeutic regimens, respectively. Calcein‐AM/PI cell viability/cytotoxicity assay and EdU cell proliferation test reveal that the platinum‐based chemotherapeutic or mono‐chemotherapeutic regimens are generally ineffective to e/mNSCLCOs because of their high IC50 values. Non‐platinum gemcitabine combined with vinorelbine achieve better anti‐e/mNSCLCOs outcome in terms of suppressed cell proliferation and 51.6–65.8% of intra‐organoid cell death. The 6 e/mNSCLCOs with EGFR mutations are sensitive to EGFR‐tyrosine kinase inhibitors (EGFR‐TKIs) in drug selective patterns. The low efficacy of conventional anti‐NSCLC drugs to e/mNSCLCOs suggests the necessity to explore alternative approaches for better adjuvant management of e/mNSCLC patients.

show abstract

Lung cancer organoids, a promising model still with long way to go

Cited by 22 publications

References 130 publications

The application of patient-derived organoid in the research of lung cancer

The application of patient-derived organoid in the research of lung cancer

Organoids in lung cancer: A teenager with infinite growth potential

Efficacy Evaluation of Adjuvant Therapeutic Drugs Against Early and Middle Stage Non‐Small Cell Lung Cancer Organoids

Contact Info

Product

Resources

About